These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16330901)

  • 1. Alpha1-adrenergic blockers: current usage considerations.
    Sica DA
    J Clin Hypertens (Greenwich); 2005 Dec; 7(12):757-62. PubMed ID: 16330901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT).
    Guthrie RM; Siegel RL
    Clin Ther; 1999 Oct; 21(10):1732-48. PubMed ID: 10566569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of alpha-blockers in the management of hypertension: a practical view.
    McInnes GT
    J Hum Hypertens; 1991 Aug; 5(4):313-6. PubMed ID: 1683406
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
    Chapman N; Chang CL; Dahlöf B; Sever PS; Wedel H; Poulter NR;
    Circulation; 2008 Jul; 118(1):42-8. PubMed ID: 18559700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of α1-blockers in the current management of hypertension.
    Li H; Xu TY; Li Y; Chia YC; Buranakitjaroen P; Cheng HM; Van Huynh M; Sogunuru GP; Tay JC; Wang TD; Kario K; Wang JG
    J Clin Hypertens (Greenwich); 2022 Sep; 24(9):1180-1186. PubMed ID: 36196467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive therapy in the geriatric patient: II. A review of the alpha1-adrenergic blocking agents.
    Studer JA; Piepho RW
    J Clin Pharmacol; 1993 Jan; 33(1):2-13. PubMed ID: 8094084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein.
    Kincaid-Smith P
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():75-83. PubMed ID: 2575178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P
    J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.
    Grimm RH; Flack JM; Grandits GA; Elmer PJ; Neaton JD; Cutler JA; Lewis C; McDonald R; Schoenberger J; Stamler J
    JAMA; 1996 May 22-29; 275(20):1549-56. PubMed ID: 8622245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide.
    Grimm RH; Flack JM; Schoenberger JA; Gonzalez NM; Liebson PR
    Am J Hypertens; 1996 May; 9(5):445-54. PubMed ID: 8735175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
    Wong GW; Laugerotte A; Wright JM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction.
    Asai T; Kushiro T; Fujita H; Kanmatsuse K
    Hypertens Res; 2005 Jan; 28(1):79-87. PubMed ID: 15969258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxazosin: a new alpha 1-adrenergic antagonist.
    Babamoto KS; Hirokawa WT
    Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthostatic hypotension: how to avoid it during antihypertensive therapy.
    Rieckert H
    Am J Hypertens; 1996 Nov; 9(11):155S-159S. PubMed ID: 8931848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
    Chrischilles E; Rubenstein L; Chao J; Kreder KJ; Gilden D; Shah H
    Clin Ther; 2001 May; 23(5):727-43. PubMed ID: 11394731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes.
    Glanz M; Garber AJ; Mancia G; Levenstein M
    Int J Clin Pract; 2001 Dec; 55(10):694-701. PubMed ID: 11777296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.